Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flow. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments. Fair value range: low $428, high $722, with mid-point at $574.
Fair value of $574.46 relies on Multi-Stage Moat Fade and DCF models capturing extended moat duration.
Next-phase growth hinges on commercial scaling of CASGEVY and clinical execution of non-opioid pain therapeutics.
Strong balance sheet with $5B in cash/marketables and robust 92% OCF-to-Net-Income conversion.
Fair value
$574
Margin of safety
+25.2%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$429.82Price
Low $428.44
Mid $574.46
High $721.5
Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flow. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments.
Cystic fibrosis therapeutics monopoly with
Cystic fibrosis therapeutics monopoly with high switching costs and IP protection
Specialized distribution and manufacturing scale
Specialized distribution and manufacturing scale
Cycle upside
Biotech expansion phase driven by favorable FDA approvals, loose capital access, and premium valuations assigned to de-risked late-stage assets.
VRTX (VRTX)'s margin set covers gross margin, operating margin, net margin, and free-cash-flow margin. The five-year trajectory is plotted so the reader can separate cyclical noise from secular trend.
Margin expansion or compression is read against the revenue base: if operating margin expands while revenue grows, that is operating leverage. If gross margin compresses, the cause (mix shift, input costs, pricing) is annotated in the numbers analysis.
Peer-relative margin context lives on the parent peers tab, which sets VRTX's gross, operating, and net margins against four to five named peers from the same archetype and sector.
FCF margin is reported alongside operating margin so the reader can spot cases where capex intensity changes the cash-conversion read even when reported profitability is steady.
FAQ
VRTX — frequently asked questions
Based on our latest analysis, VRTX looks meaningfully undervalued. The current price is $430 versus a composite fair-value midpoint of $574 (range $428–$722), which implies roughly 33.6% upside to the midpoint.
Our composite fair-value range for VRTX is $428–$722, with a midpoint of $574. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for VRTX's archetype.
Our current rating for VRTX is Strong Buy with a confidence score of 88/100. Strong Buy. Vertex offers highly visible base cash flows from its CF monopoly combined with compelling optionality from its non-opioid pain and gene-editing pipelines. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for VRTX are: CASGEVY Launch Stalls; Pain Pipeline Failure; CF Monopoly Disruption. The single biggest risk is CASGEVY Launch Stalls: Severe underperformance in commercial scaling of CASGEVY due to treatment center bottlenecks or reimbursement pushback, impairing growth.
Our current rating for VRTX is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($428–$722) versus the current price of $430.
VRTX is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for VRTX.
